Treatment of Mild-moderate Clostridium Difficile Infection (CDI)
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Patients diagnosed to have mild-moderate CDI will be randomized to receive IM-01 egg-derived
anti-C. difficile polyclonal antibodies in increasing dosages, twice daily, for a total of 10
- 14 days. Resolution of diarrhea and other symptoms and fecal test parameters will be used
to assess clinical effectiveness of Immunotherapy with IM-01 antibodies. Patients will be
followed for recurrence of CDI. Subjects who are assessed as non-respondents to IM-01 will be
reassessed and treated with standard of care CDI antibiotics for 10 -14 days.